Expression of the Decay-Accelerating Factor (CD55) in Renal Transplants-A Possible Prediction Marker of Allograft Survival
Expression of the Decay-Accelerating Factor (CD55) in Renal Transplants-A Possible Prediction Marker of Allograft Survival
复制标题
DOI：
10.1097/tp.0b013e3181b0517d
复制
发表时间：
2009-08-27
期刊：
影响因子：
6.2
通讯作者：
Nadasdy, Tibor
中科院分区：
文献类型：
--
作者：
Brodsky, Sergey V.;Nadasdy, Gyongyi M.;Nadasdy, Tibor
背景。衰变加速因子（CD55）加速C3和C5转化酶的衰变，参与经典和替代补体激活途径。补体激活在抗体介导的同种异体移植排斥反应（AMR）中起主要作用；C4d作为AMR的标记。新出现的证据表明CD55在AMR的发病机制中起重要作用。本研究旨在探讨CD55在同种异体肾移植中的表达，并探讨其与C4d表达、同种异体肾移植存活率、血清肌酐（SC）变化的关系。我们对200例异体肾移植功能障碍患者进行了活检，评估了小管周围毛细血管（PTC） C4d和CD55的表达。我们发现无PTC C4d染色的患者SC和PTC CD55染色模式的变化有显著相关性。在这些患者中，阴性、局灶性和弥漫性PTC CD55染色亚组的SC分别比基线增加2.2+0.34、1.7+0.36和0.93+0.24 mg/dL。PTC CD55弥漫性染色亚组移植肾的存活率高于PTC CD55阴性染色亚组。这些数据表明，CD55表达对PTC C4d阴性肾移植具有保护作用，PTC CD55表达模式可作为无AMR证据患者移植肾存活的潜在标志物。
Background. Decay-accelerating factor (CD55) accelerates the decay of C3 and C5 convertases, participating in classical and alternative complement activation pathways. Complement activation plays a major role in antibody-mediated rejection of allografts (AMR); C4d is used as a marker of AMR. Emerging evidence suggests an important role of CD55 in the pathogenesis of AMR. The aim of this study was to investigate the expression of CD55 in renal allografts and to correlate it with the expression of C4d, allograft survival, changes in serum creatinine (SC).Methods. More than 200 renal allograft biopsies, performed for allograft dysfunction, were assessed for peritubular capillary (PTC) C4d and CD55 expression.Results. We found significant correlation between changes in SC and PTC CD55 staining pattern in patients with no PTC C4d staining. In these patients, SC increased from baseline by 2.2+0.34, 1.7+0.36, and 0.93+0.24 mg/dL in negative, focal, and diffuse PTC CD55 staining subgroups, respectively. Survival of renal allografts was better in diffuse PTC CD55 staining subgroup than in negative PTC CD55 staining subgroup.Conclusions. These data suggest that CD55 expression has a protective effect on PTC C4d negative renal allografts, and the pattern of PTC CD55 expression may be used as a potential marker of renal allograft survival in patients with no evidence of AMR.